Brokerage Firm Rating on Celgene Corporation (CELG)

Celgene Corporation (CELG) : The consensus on Celgene Corporation (CELG) based on 18 analyst recommendation on the company stock is 1.33, which is interpreted as a Strong Buy recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 15 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 3 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.

Celgene Corporation (CELG) : 15 Wall Street analysts covering Celgene Corporation (CELG) believe that the average level the stock could reach for the short term is $142.47. The maximum price target given is $162 and the minimum target for short term is around $120, hence the standard deviation is calculated at $12.1.


For the current week, the company shares have a recommendation consensus of Buy. Celgene Corporation (NASDAQ:CELG): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $112.81 and $112.27 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $113.94. The buying momentum continued till the end and the stock did not give up its gains. It closed at $113.81, notching a gain of 1.14% for the day. The total traded volume was 2,766,176 . The stock had closed at $112.53 on the previous day.

In a related news,The director officer (see remarks) of Celgene Corp /De/, Hugin Robert J sold 100,000 shares at $110 on July 28, 2016. The Insider selling transaction had a total value worth of $11,000,000. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.

Celgene Corporation (Celgene), together with its subsidiaries, is an integrated biopharmaceutical company engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. The Companys primary commercial stage products include REVLIMID (lenalidomide), ABRAXANE, POMALYST/IMNOVID, VIDAZA, azacitidine for injection (generic version of VIDAZA), THALOMID (sold as THALOMID or Thalidomide Celgene outside the United States), OTEZLA (apremilast) and ISTODAX (romidepsin). Celgene is involved in research in a range of scientific areas designed to deliver therapies, targeting areas, including intracellular signaling pathways, protein homeostasis and epigenetics in cancer and immune cells, immunomodulation in cancer and autoimmune diseases, and therapeutic application of cell therapies.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.